Alzamend Neuro, Inc. – NASDAQ:ALZN
Alzamend Neuro stock price today
Alzamend Neuro stock price monthly change
Alzamend Neuro stock price quarterly change
Alzamend Neuro stock price yearly change
Alzamend Neuro key metrics
Market Cap | 6.41M |
Enterprise value | N/A |
P/E | -3.03 |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | N/A |
Price/Book | 8.64 |
PEG ratio | 0.02 |
EPS | -2.38 |
Revenue | N/A |
EBITDA | -15.23M |
Income | -15.26M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeAlzamend Neuro stock price history
Alzamend Neuro stock forecast
Alzamend Neuro financial statements
| Apr 2022 | 0 | -3.86M | |
|---|---|---|---|
| Jan 2023 | 0 | -5.42M | |
| Apr 2023 | 0 | -3.30M | |
| Jan 2024 | 0 | -2.66M |
| 2028 | 132.70M | 9.03M | 6.81% |
|---|
Analysts Price target
Financials & Ratios estimates
| 2024-07-30 | -2.75 | -13.35 |
|---|---|---|
| 2024-09-11 | -2.38 | -1.25 |
| 2024-12-11 | -2.38 | -0.4 |
| Oct 2022 | 10424876 | 1.63M | 15.71% |
|---|---|---|---|
| Jan 2023 | 8501978 | 2.64M | 31.08% |
| Apr 2023 | 5915625 | 2.87M | 48.52% |
| Jan 2024 | 852636 | 5.04M | 591.87% |
| Apr 2022 | -1.56M | -106.45K | 3.94M |
|---|---|---|---|
| Jan 2023 | -1.80M | 0 | 0 |
| Apr 2023 | -2.23M | 0 | 200 |
| Jan 2024 | -2.03M | 0 | 2.11M |
Alzamend Neuro alternative data
| Aug 2023 | 4 |
|---|---|
| Sep 2023 | 4 |
| Oct 2023 | 4 |
| Nov 2023 | 4 |
| Dec 2023 | 4 |
| Jan 2024 | 4 |
| Feb 2024 | 4 |
| Mar 2024 | 4 |
| Apr 2024 | 4 |
| May 2024 | 4 |
| Jun 2024 | 4 |
| Jul 2024 | 4 |
Alzamend Neuro other data
| Period | Buy | Sel |
|---|---|---|
| May 2023 | 18000 | 0 |
| Sep 2023 | 53000 | 0 |
| Dec 2023 | 700 | 0 |
| Jan 2024 | 1226220 | 0 |
| Mar 2024 | 780780 | 0 |
| Apr 2024 | 1334 | 0 |
| Insider | Compensation |
|---|---|
Mr. Stephan Jackman (1976) Chief Executive Officer & Director | $225,000 |
Mr. Kenneth S. Cragun CPA (1961) Senior Vice President of Fin. | $100,000 |
Mr. Henry C. W. Nisser Esq. (1968) Executive Vice President, Gen. Counsel & Director | $50,000 |
-
What's the price of Alzamend Neuro stock today?
One share of Alzamend Neuro stock can currently be purchased for approximately $2.37.
-
When is Alzamend Neuro's next earnings date?
Unfortunately, Alzamend Neuro's (ALZN) next earnings date is currently unknown.
-
Does Alzamend Neuro pay dividends?
No, Alzamend Neuro does not pay dividends.
-
How much money does Alzamend Neuro make?
Alzamend Neuro has a market capitalization of 6.41M. Alzamend Neuro made a loss 9.95M US dollars in net income (profit) last year or -$0.4 on an earnings per share basis.
-
What is Alzamend Neuro's stock symbol?
Alzamend Neuro, Inc. is traded on the NASDAQ under the ticker symbol "ALZN".
-
What is Alzamend Neuro's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Alzamend Neuro?
Shares of Alzamend Neuro can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Alzamend Neuro's key executives?
Alzamend Neuro's management team includes the following people:
- Mr. Stephan Jackman Chief Executive Officer & Director(age: 49, pay: $225,000)
- Mr. Kenneth S. Cragun CPA Senior Vice President of Fin.(age: 64, pay: $100,000)
- Mr. Henry C. W. Nisser Esq. Executive Vice President, Gen. Counsel & Director(age: 57, pay: $50,000)
-
How many employees does Alzamend Neuro have?
As Jul 2024, Alzamend Neuro employs 4 workers.
-
When Alzamend Neuro went public?
Alzamend Neuro, Inc. is publicly traded company for more then 4 years since IPO on 15 Jun 2021.
-
What is Alzamend Neuro's official website?
The official website for Alzamend Neuro is alzamend.com.
-
Where are Alzamend Neuro's headquarters?
Alzamend Neuro is headquartered at 3500 Lenox Road NE, Atlanta, GA.
-
How can i contact Alzamend Neuro?
Alzamend Neuro's mailing address is 3500 Lenox Road NE, Atlanta, GA and company can be reached via phone at +84 47226333.
Alzamend Neuro company profile:
Alzamend Neuro, Inc.
alzamend.comNASDAQ
4
Biotechnology
Healthcare
Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001 that is in Phase II clinical trial, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and AL002 that completed preclinical stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.
Atlanta, GA 30326
CIK: 0001677077
ISIN: US02262M4078
CUSIP: 02262M308
